Calquence
AstraZeneca shares positive interim results from phase 3 lymphoma trial
May 3, 2024Medical Communications AstraZeneca, Calquence, Oncology, clinical trial, lymphoma
AstraZeneca has announced positive high-level results from an interim analysis of the ECHO phase 3 trial, which assessed Calquence (acalabrutinib) …
AstraZeneca’s Calquence fails to improve survival rates in coronavirus patients
November 12, 2020Business Services AZ, AstraZeneca, Calquence
AstraZeneca’s Calquence has failed to improve survival rates and prevent lung failure in patients hospitalised with COVID-19. Calquence (acalabrutinib) is …
Two CHMP recommendations for AstraZeneca: Imfinzi in first-line lung cancer, Calquence in chronic lymphocytic leukaemia
July 27, 2020Sales and Marketing AstraZeneca, CHMP, Calquence, EMA, Imfinzi
AstraZeneca has secured two new recommendations for approval of its products from the European Medicines Agency’s Committee for Medicinal Products …
AstraZeneca’s BTK inhibitor Calquence shows promise in aiding recovery of severe COVID-19 patients
June 8, 2020Research and Development, Sales and Marketing AstraZeneca, COVID-19, Calquence, coronavirus, pharma
AstraZeneca has revealed more data in its efforts to find an effective therapy for those affected by the novel coronavirus.
AstraZeneca to pit blood cancer drug Calquence against COVID-19 with the company’s fastest-ever trial launch
April 14, 2020Manufacturing and Production, Research and Development AstraZeneca, COVID-19, Calquence, coronavirus, pharma
As the R&D race against COVID-19 continues, AstraZeneca is poised to launch a global, multicentre clinical trial to test its …
AstraZeneca’s trial of leukaemia drug Calquence yields positive results
December 9, 2019Sales and Marketing AstraZeneca, Calquence, leukaemia, phase 3
AstraZeneca confirmed it had recorded positive results from its Phase 3 trial of Calquence plus obinutuzumab in leukaemia. The trial …
FDA approves AstraZeneca’s Calquence in chronic lymphoma
November 25, 2019Sales and Marketing Astrazenaca, Calquence, FDA, Health Canada, leukaemia, oncology
The FDA has approved AstraZeneca’s BTK inhibitor Calquence (acalabrutinib) in the treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic …
AstraZeneca’s Calquence shows strength in most common adult leukaemia
June 6, 2019Research and Development AstraZeneca, Calquence, chronic lymphocytic leukaemia, pharma
AstraZeneca has unveiled new Phase 3 data for Calquence (acalabrutinib) in treatment-naïve chronic lymphocytic leukaemia, showing that the drug met …
AZ ends Calquence trial early after Phase 3 success in chronic lymphocytic leukaemia
May 8, 2019Research and Development AstraZeneca, Calquence, pharma
AstraZeneca has unveiled new Phase 3 data on the efficacy of its Bruton tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) in …
